Progenics Signs an Exclusive Agreement with ROTOP Pharmaka to Develop and Commercialize Imaging Agent 1404 for Prostate Cancer in Europe


  • Progenics to receive royalties on sales of 1404 in EU. ROTOP to get an exclusive license to develop & commercialize 1404 in EU and is also responsible for regulatory approvals
  • The focus of the agreement is to expand ROTOP’s PSMA targeted prostate cancer portfolio and to accelerate the development of 1404 for treating prostate cancer in Europe
  • Progenic’s 1404 is a prostate specific membrane antigen (PSMA) targeting SPECT/CT imaging agent labeled with technetium-99m, designed for the detection of primary and metastatic prostate cancer with its expected clinical trials onset in H1’20

Click here to read full press release/ article | Ref: Progenics | Image: Annual Reports